胰岛素泵联合磷酸西格列汀治疗初诊2 型糖尿病患者的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Insulin pump combined with Sitagliptin Phosphate in the treatment of newly diagnosed type 2 diabetes mellitus patients.Methods A total of 88 newly diagnosed type 2 diabetes mellitus patients who were treated in the First People′s Hospital of Jiujiang City from January 2018 to December 2019 were selected as the study subjects.According to random number table method, they were divided into control group(44 cases) and observation group (44 cases).The control group was treated with Insulin pump alone, and the observation group was treated with Sitagliptin Phosphate based on the control group.The blood glucose, insulin resistance, insulin dosage, time of reaching target of glucose and adverse reactions were compared between the two groups.Results There was no statistically significant difference in the blood glucose between the two groups before treatment (P>0.05).The levels of glycated hemoglobin (HbA1c), fasting plasma glucose (FPG) and 2 hours postprandial blood glucose (2 h PG)in the two groups after treatment were lower than those before treatment, with statistically significant differences (P<0.05).The HbA1c, FPG and 2 h PG in the observation group ([6.52±0.57] %, [5.68±0.51] mmol/L, [7.52±1.14] mmol/L] were lower than those in the control group ([7.34±0.85] %, [6.75±0.73] mmol/L, [8.69±1.23] mmol/L] after treatment, with statistically significant differences (P<0.05).There were no statistically significant differences in the homeostasis model assessment β (HOMA-β) and homeostasis model assessment-insulin resistance (HOMA-IR) between the two groups before treatment (P>0.05).The HOMA-β levels of the two groups after treatment were higher than those before treatment, and the HOMA-IR levels of the two groups after treatment were lower than those before treatment,with statistically significant differences (P<0.05).After treatment, HOMA-β in the observation group was (65.82±6.14),higher than that in the control group of (59.41±5.73), and HOMA-IR in the observation group was (2.95±0.63), lower than that in the control group of (3.41±0.85), the differences were statistically significant (P<0.05).The insulin dosage in the observation group ([14.67±4.31] U) was less than that in the control group ([20.15±5.16] U), the time of reaching target of glucose in the observation group ([8.31±1.25] d) was shorter than that in he control group ([11.84±2.69] d), and the total incidence of adverse reactions in observation group (4.55%) was lower than that in control group (20.45%), with statistically significant differences (P<0.05).Conclusion Insulin pump combined with Sitagliptin Phosphate can stabilize the blood glucose of newly diagnosed type 2 diabetes mellitus patients, improve insulin resistance, and enhance islet β-cell function, which is safe and reliable.

Key words： Type 2 diabetes mellitus Insulin pump Sitagliptin Phosphate Insulin resistance Insulin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	KANG Luchen
	LI Wenbin
	LAN Hao
	LIU Bingling

Cite this article:

KANG Luchen,LI Wenbin,LAN Hao, et al. Clinical effect of Insulin pump combined with Sitagliptin Phosphate in the treatment of newly diagnosed type 2 diabetes mellitus patients[J]. 中国当代医药, 2021, 28(36): 47-50.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I36/47

[1]	刘晶，赵培，陈稳，等.实时胰岛素泵治疗对2 型糖尿病患者氧化应激及血管内皮功能的影响[J].河北医科大学学报，2019，40（12）：1380-1383.
[2]	王晓军，翟铁，郝凤杰.胰岛素泵强化治疗后阿格列汀对初诊2 型糖尿病的效果及对IL-6 的影响[J].检验医学与临床，2019，16（16）：2306-2308.
[3]	刘高虹，任小军，于为民.西格列汀对糖尿病大鼠肾脏二肽基肽酶-4 表达影响的实验研究[J].中国药物与临床，2019，19（14）：2353-2354.
[4]	陈鑫，张菁.西格列汀在糖尿病治疗中的药理作用及临床评价[J].中国医药，2018，13（3）：467-470.
[5]	中华医学会糖尿病学分会.中国2 型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[6]	李颖，马维青，刘尚全.西格列汀在预混胰岛素疗效不佳的2 型糖尿病患者中的应用效果[J].广西医学，2017，39（12）：1852-1854.
[7]	刘阳，杨静，任毅，等.磷酸西格列汀联合二甲双胍治疗2 型糖尿病的临床疗效观察[J].中西医结合心脑血管病杂志，2018，16（12）：1725-1727.
[8]	朱菊训，刘玲，闫金玲，等.胰岛素泵治疗在脑卒中合糖尿病病人肠内营养实施中的应用评价[J].肠外与肠内营养，2019，26（4）：223-227.
[9]	王秋锋，金春华.初诊断2 型糖尿病患者短期胰岛素泵强化治疗后不同治疗方案对胰岛功能的影响[J].中国慢性病预防与控制，2019，27（5）：377-380.
[10]	张鹏.西格列汀联合胰岛素治疗成人隐匿性自身免疫性糖尿病患者的疗效[J].中国药物与临床，2019，19（5）：765-766.
[11]	韩松梅，金昕晔，臧丽，等.磷酸西格列汀对接受胰岛素强化治疗的初发2 型糖尿病患者早期降糖疗效和血糖波动性的影响[J].解放军医学院学报，2019，40（1）：7-10.
[12]	李玉苏，窦连军，王犇，等.西格列汀治疗2 型糖尿病的疗效及对胰岛β 细胞功能的影响的观察[J].贵州医药，2017，41（12）：1273-1275.
[13]	周焰，韩亮.磷酸西格列汀联合二甲双胍治疗初发型2型糖尿病患者的疗效[J].安徽医学，2017，38（4）：476-478.
[14]	张青立，申姗姗.天麦消渴片联合西格列汀治疗肥胖型2 型糖尿病的临床研究[J].现代药物与临床，2017，32（12）：2465-2468.
[15]	顾蕾，王博，张玄娥，等.西格列汀对初诊2 型糖尿病患者短期胰岛素泵强化治疗后胰岛细胞功能的影响[J].贵州医药，2019，43（10）：1583-1585.